City firm partners with CSIR for clinical trial of Niclosamide
The Hindu
‘Niclosamide is generic, affordable and easily available’
Council of Scientific & Industrial Research (CSIR), in collaboration with Hyderabad based Laxai Life Sciences Pvt. Ltd., has initiated Phase-II clinical trial with anti-helminitic drug Niclosamide for treatment of COVID-19. The trial is a multi-centric, randomised, open label clinical study to evaluate efficacy, safety and tolerability of Niclosamide for the treatment of hospitalised patients. It was extensively used in the past for treatment of tapeworm’s infection in adults and children. The safety profile of this drug has been tested over time and has been found to be safe at different dose levels. CSIR Director-General Shekhar C. Mande expressed happiness over SEC recommendations to conduct the Phase II clinical trial using Niclosamide, which is generic, affordable and easily available in India and therefore can be made available to the population, said a press release on Sunday.More Related News